BB&T Securities LLC Sells 13,707 Shares of Cerus Co. (CERS)

BB&T Securities LLC decreased its stake in Cerus Co. (NASDAQ:CERS) by 33.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 27,400 shares of the biotechnology company’s stock after selling 13,707 shares during the period. BB&T Securities LLC’s holdings in Cerus were worth $150,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Jump Trading LLC acquired a new stake in shares of Cerus in the first quarter valued at about $104,000. Teacher Retirement System of Texas acquired a new stake in shares of Cerus in the fourth quarter valued at about $126,000. MetLife Investment Advisors LLC acquired a new stake in shares of Cerus in the fourth quarter valued at about $197,000. Alambic Investment Management L.P. acquired a new stake in shares of Cerus in the first quarter valued at about $225,000. Finally, Two Sigma Investments LP acquired a new stake in shares of Cerus in the fourth quarter valued at about $249,000. 60.09% of the stock is owned by institutional investors.

Several brokerages have recently weighed in on CERS. BidaskClub raised Cerus from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 1st. Zacks Investment Research cut Cerus from a “buy” rating to a “hold” rating in a research note on Friday, April 13th. ValuEngine raised Cerus from a “hold” rating to a “buy” rating in a research note on Friday, May 4th. Finally, BTIG Research restated a “hold” rating on shares of Cerus in a research report on Saturday, March 10th. Two research analysts have rated the stock with a hold rating, three have issued a buy rating and two have given a strong buy rating to the company. Cerus has a consensus rating of “Buy” and a consensus target price of $5.44.

Shares of Cerus opened at $6.62 on Thursday, Marketbeat Ratings reports. Cerus Co. has a one year low of $2.10 and a one year high of $7.31. The company has a debt-to-equity ratio of 0.33, a quick ratio of 5.10 and a current ratio of 5.66. The stock has a market cap of $913.81 million, a P/E ratio of -11.82 and a beta of 1.81.

Cerus (NASDAQ:CERS) last announced its earnings results on Tuesday, May 8th. The biotechnology company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.01. Cerus had a negative return on equity of 111.19% and a negative net margin of 111.46%. The company had revenue of $13.56 million for the quarter, compared to analyst estimates of $12.22 million. During the same quarter in the prior year, the company earned ($0.18) EPS. The firm’s revenue for the quarter was up 93.4% compared to the same quarter last year. equities research analysts expect that Cerus Co. will post -0.45 earnings per share for the current fiscal year.

In related news, insider Richard J. Benjamin sold 8,631 shares of the company’s stock in a transaction dated Friday, May 11th. The stock was sold at an average price of $6.69, for a total transaction of $57,741.39. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Carol Moore sold 60,841 shares of the stock in a transaction that occurred on Friday, May 11th. The stock was sold at an average price of $6.26, for a total value of $380,864.66. Following the completion of the transaction, the senior vice president now owns 60,841 shares in the company, valued at approximately $380,864.66. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 292,972 shares of company stock worth $1,913,341. 6.80% of the stock is owned by corporate insiders.

Cerus Company Profile

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products.

Want to see what other hedge funds are holding CERS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cerus Co. (NASDAQ:CERS).

Institutional Ownership by Quarter for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply